Selective glucocorticoid receptor modulator
(重定向自SEGRA)

![The benzopyranoquinoline A 276575, an example of a SEGRA with a more corticosteroid-like structure[6]](/uploads/202502/10/A_276575_structure.svg3857.png)

![RU 24858, a SEGRA with steroid structure[5]](/uploads/202502/10/RU_24858_skeletal.svg3857.png)
Selective glucocorticoid receptor modulators (SEGRMs) and selective glucocorticoid receptor agonists (SEGRAs) formerly known as dissociated glucocorticoid receptor agonists (DIGRAs) are a class of experimental drugs designed to share many of the desirable anti-inflammatory, immunosuppressive, or anticancer properties of classical glucocorticoid drugs but with fewer side effects such as skin atrophy. Although preclinical evidence on SEGRAMs’ anti-inflammatory effects are culminating, currently, the efficacy of these SEGRAMs on cancer are largely unknown.